Related parties accounts payable and accrued expenses
391,081
436,482
235,900
92,149
Research and development contract liabilities
238,435
232,138
235,155
256,147
Operating lease obligations, current
595,418
595,418
-
-
Accrued offering costs
-
-
-
188,826
Series b convertible preferred stock 8 cumulative dividend payable
-
69,073
50,367
-
Total current liabilities
1,224,934
1,333,111
521,422
537,122
Operating lease obligations, long-term
461,772
438,959
-
-
Total liabilities
1,686,706
1,772,070
-
-
Preferred stock, value
-
1,731,569
2,553,359
-
Common stock, 0.0001 par value 100,000,000 shares authorized 11,632,944 and 8,790,102 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively
1,162
879
570
276
Additional paid-in capital
67,944,759
66,008,824
57,891,644
54,204,101
Accumulated deficit
-60,000,889
-58,077,213
-55,533,319
-53,552,921
Total lixte biotechnology stockholders equity
7,945,032
9,664,059
4,912,254
651,456
Non-controlling interest
1,233,560
1,297,492
-
-
Total stockholders equity
9,178,592
10,961,551
-
-
Total liabilities and stockholders equity
10,865,298
12,733,621
5,433,676
1,188,578
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.